Skip to main content
Clinical Trials/NCT06270706
NCT06270706
Recruiting
Phase 1

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

Pliant Therapeutics, Inc.9 sites in 1 country124 target enrollmentAugust 30, 2023

Overview

Phase
Phase 1
Intervention
PLN-101095
Conditions
Metastatic Solid Tumor
Sponsor
Pliant Therapeutics, Inc.
Enrollment
124
Locations
9
Primary Endpoint
Proportion of participants with treatment-emergent adverse events and serious adverse events per CTCAE Version 5.0.
Status
Recruiting
Last Updated
12 days ago

Overview

Brief Summary

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.

The study will consist of 2 main parts:

  • Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
  • Part 2: Dose-expansion cohorts using Simon's 2-stage design
Registry
clinicaltrials.gov
Start Date
August 30, 2023
End Date
June 1, 2030
Last Updated
12 days ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Has histologically or cytologically confirmed advanced or metastatic solid tumor
  • Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
  • Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
  • Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
  • At least 1 measurable lesion, as defined by RECIST v1.1
  • Estimated survival of ≥3 months
  • Have adequate bone marrow and organ function.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding

Exclusion Criteria

  • Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
  • Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
  • Has a diagnosis of immunodeficiency or use of systemic steroids \>10 mg/day
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years
  • Has known active CNS metastases (brain and/or leptomeningeal metastases)
  • Has significant cardiac disease
  • Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
  • Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095

Arms & Interventions

Part 1 Dose Escalation - 250 mg BID

Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: PLN-101095

Part 2 Dose Expansion - ccRCC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)

Intervention: PLN-101095

Part 2 Dose Expansion - TMB-high solid tumors

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors

Intervention: Pembrolizumab

Part 1 Dose Escalation - 250 mg BID

Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: Pembrolizumab

Part 1 Dose Escalation - 2000 mg BID

PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: PLN-101095

Part 1 Dose Escalation - 1000 mg BID

PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: Pembrolizumab

Part 1 Dose Escalation - 500 mg BID

PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: PLN-101095

Part 1 Dose Escalation - 500 mg BID

PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: Pembrolizumab

Part 2 Dose Expansion - NSCLC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)

Intervention: PLN-101095

Part 1 Dose Escalation - 1000 mg BID

PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: PLN-101095

Part 1 Dose Escalation - 1000 mg TID

PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors

Intervention: PLN-101095

Part 1 Dose Escalation - 1000 mg TID

PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors

Intervention: Pembrolizumab

Part 2 Dose Expansion - NSCLC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)

Intervention: Pembrolizumab

Part 1 Dose Escalation - 2000 mg BID

PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors

Intervention: Pembrolizumab

Part 2 Dose Expansion - ccRCC

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)

Intervention: Pembrolizumab

Part 2 Dose Expansion - TMB-high solid tumors

PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors

Intervention: PLN-101095

Outcomes

Primary Outcomes

Proportion of participants with treatment-emergent adverse events and serious adverse events per CTCAE Version 5.0.

Time Frame: Signing ICF until 16 weeks after end of study treatment regimen

Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.

Time Frame: First dose to 35 days

Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2

Time Frame: Day 1 until 16 weeks after end of study treatment regimen

Proportion of participants with treatment-emergent adverse events and serious adverse events.

Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2

Time Frame: First dose to disease progression or death from any cause, whichever occurs first.

Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1.

Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2

Time Frame: First dose to 35 days

Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.

Secondary Outcomes

  • Time to maximum observed concentration (Tmax) to characterize the plasma pharmacokinetics (PK).(First dose until 10 weeks)
  • Area under the concentration-time curve over a dosing interval (AUC0-τ) to characterize the plasma pharmacokinetics (PK).(First dose until 10 weeks)
  • Disease control rate (DCR) is defined by the proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1.(Day 1 until end of study treatment regimen)
  • Objective response rate (ORR) is defined by the proportion of participants with an iCR or iPR per iRECIST Version 1.1.(Day 1 until end of study treatment regimen)
  • Maximum observed plasma concentration (Cmax) to characterize the plasma pharmacokinetics (PK).(First dose until 10 weeks)
  • PK of PLN-101095 monotherapy in Parts 1 and 2(Day 14, 0 to up to 12 hours)
  • Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2(First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first)
  • Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2(First dose to progression or death from any cause, whichever occurs first)

Study Sites (9)

Loading locations...

Similar Trials

Related News